Vidal Health partners Serum Institute to widen access to HPV vaccine

MUMBAI: Bajaj Finserv-subsidiary Vidal Health has partnered with Serum Institute of India (SII) to widen access to the HPV vaccine from Oct 1.

The programme, offered through Vidal’s digital platform, will be cashless and paper-free, covering booking, consent, certification, reminders, and adherence monitoring. Vaccines will be available directly, with options for workplace or clinic administration at affordable prices.


Sanjiv Bajaj, chairman and managing director of Bajaj Finserv, said: “Healthcare in India is experiencing a fundamental shift from reactive, post-illness care to preventive care, driven by awareness and transformative initiatives like Ayushman Bharat. At Bajaj Finserv Health, we are shaping this change by building a digital platform that empowers people to stay healthy, with preventive healthcare at its core. Our collaboration with Serum Institute marks a strong start to our vaccination programme.”


Adar Poonawalla, CEO of SII, said: “The HPV vaccine is an important step in preventing cervical cancer, but wider access and awareness are key to its impact. Our collaboration with Vidal Health helps bridge that gap by using technology to deliver the vaccine more efficiently and at scale.”